Correlation Between Crinetics Pharmaceuticals and Veracyte

Can any of the company-specific risk be diversified away by investing in both Crinetics Pharmaceuticals and Veracyte at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Crinetics Pharmaceuticals and Veracyte into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Crinetics Pharmaceuticals and Veracyte, you can compare the effects of market volatilities on Crinetics Pharmaceuticals and Veracyte and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Crinetics Pharmaceuticals with a short position of Veracyte. Check out your portfolio center. Please also check ongoing floating volatility patterns of Crinetics Pharmaceuticals and Veracyte.

Diversification Opportunities for Crinetics Pharmaceuticals and Veracyte

0.54

Correlation Coefficient

Crinetics Pharmaceuticals  Veracyte

Very weak diversification

The 3 months correlation between Crinetics and Veracyte is 0.54. Overlapping area represents the amount of risk that can be diversified away by holding Crinetics Pharmaceuticals and Veracyte in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Veracyte and Crinetics Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Crinetics Pharmaceuticals are associated (or correlated) with Veracyte. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Veracyte has no effect on the direction of Crinetics Pharmaceuticals i.e., Crinetics Pharmaceuticals and Veracyte go up and down completely randomly.

Pair Corralation between Crinetics Pharmaceuticals and Veracyte

Given the investment horizon of 90 days Crinetics Pharmaceuticals is expected to generate 3.07 times less return on investment than Veracyte. But when comparing it to its historical volatility, Crinetics Pharmaceuticals is 1.15 times less risky than Veracyte. It trades about 0.08 of its potential returns per unit of risk. Veracyte is currently generating about 0.21 of returns per unit of risk over similar time horizon. If you would invest  3,029  in Veracyte on August 31, 2024 and sell it today you would earn a total of  1,260  from holding Veracyte or generate 41.6% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

Crinetics Pharmaceuticals  vs.  Veracyte

Crinetics Pharmaceuticals

Risk-Adjusted Performance

6 of 100

Modest

Compared to the overall equity markets, risk-adjusted returns on investments in Crinetics Pharmaceuticals are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. In spite of fairly unsteady basic indicators, Crinetics Pharmaceuticals may actually be approaching a critical reversion point that can send shares even higher in December 2024.

Veracyte

Risk-Adjusted Performance

16 of 100

Solid

Compared to the overall equity markets, risk-adjusted returns on investments in Veracyte are ranked lower than 16 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively weak basic indicators, Veracyte unveiled solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Crinetics Pharmaceuticals and Veracyte

The main advantage of trading using opposite Crinetics Pharmaceuticals and Veracyte positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Crinetics Pharmaceuticals position performs unexpectedly, Veracyte can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Veracyte will offset losses from the drop in Veracyte's long position.

The idea behind Crinetics Pharmaceuticals and Veracyte pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.